Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

  1. Zhe Lv
  2. Yong-Qiang Deng
  3. Qing Ye
  4. Lei Cao
  5. Chun-Yun Sun
  6. Changfa Fan
  7. Weijin Huang
  8. Shihui Sun
  9. Yao Sun
  10. Ling Zhu
  11. Qi Chen
  12. Nan Wang
  13. Jianhui Nie
  14. Zhen Cui
  15. Dandan Zhu
  16. Neil Shaw
  17. Xiao-Feng Li
  18. Qianqian Li
  19. Liangzhi Xie
  20. Youchun Wang
  21. Zihe Rao
  22. Cheng-Feng Qin
  23. Xiangxi Wang

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

In response to infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the immune system makes antibodies, many of which target the spike protein, a key player in host cell entry. Antibodies that potently neutralize the virus hold promise as therapeutics and could inform vaccine design. Lv et al. report a humanized monoclonal antibody that protected against SARS-CoV-2 in a mouse model. The cryo–electron microscopy structure, together with biochemical, cellular, and virological studies, showed that the antibody acts by binding to the receptor-binding domain of the spike and blocking its attachment to the host receptor.

Science , this issue p. 1505

Article activity feed

  1. Version published to 10.1126/science.abc5881
  2. Version published to 10.1101/2020.06.02.129098v2 on bioRxiv
  3. ScreenIT

    SciScore for 10.1101/2020.06.02.129098: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: Thank you for sharing your data.

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).

    Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 20. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  4. Version published to 10.1101/2020.06.02.129098v1 on bioRxiv